EUCTR2015-005699-21-CZ进行中（未招募）1 期
An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab,Pomalidomide and Dexamethasone in Relapsed and Refractory MultipleMyeloma
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 417
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Refractory or relapsed and refractory multiple myeloma
- •- Measurable disease
- •- Have received = 2 lines of prior therapy which must have included an
- •immune modulatory drug (IMiD) and a proteasome inhibitor alone or in
- •combination
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 125
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 292
排除标准
- •- Solitary bone or extramedullary plasmacytoma disease only
- •- Active plasma cell leukemia
研究者
相似试验
进行中（未招募）
1 期
Phase 3 Study of Combinations of Nivolumab, Elotuzumab, Pomalidomideand Dexamethasone in Multiple Myelomarelapsed and refractory Multiple MyelomaMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2015-005699-21-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO512
进行中（未招募）
1 期
Phase 3 Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myelomarelapsed and refractory Multiple MyelomaMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000054086EUCTR2015-005699-21-PLBristol-Myers Squibb International Corporation512
进行中（未招募）
1 期
Phase 3 Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple MyelomaEUCTR2015-005699-21-ESBristol-Myers Squibb International Corporation170
进行中（未招募）
1 期
Phase 3 Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myelomarelapsed and refractory Multiple MyelomaMedDRA version: 19.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2015-005699-21-NOBristol-Myers Squibb International Corporation512
进行中（未招募）
1 期
Phase 3 Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myelomarelapsed and refractory Multiple MyelomaMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2015-005699-21-GRBristol-Myers Squibb International Corporation512